PLUS THERAPEUTICS, Inc. (PSTV)

PSTV · BiotechSign Pipeline

Pipeline Overview

Therapeutic Focus: Biotech / Pharmasrc

Signal Snapshot

Clinical Trials (ClinicalTrials.gov aggregate)

Catalyst Records

Publication on Record

ClinicalTrials.gov aggregate as of 2026-09-29. Source

Recent Publications

Prolonged survival after systemic immune reactivation by aglatimagene besadenovec plus valacyclovir in immune checkpoint inhibitor-refractory non-small cell lung cancer. — J Immunother Cancer (2026) PMID 42805763

Get real-time catalyst alerts, analyst signals, dilution risk scores, and full pipeline data for PLUS THERAPEUTICS, Inc..

Full PSTV Data Sign Up Free

Primary Sources

Company identity
Therapeutic indication
Clinical trial aggregate
Publication 42805763

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.